We coined and trademarked TechBio not just to be different, although there’s nothing wrong with that. We wanted to demonstrate the new era of medicine where advances in sequencing, compute, storage, data management, data science, use of complex biological systems, genetic programming, synthetic biology all ushered a new way in which we would approach healthcare.
We also cared to have impact that had global reach. Our GPs, Pioneers, Fellows and founders stem from many parts of the world and represent over 30 countries. To us TechBio finally allows us to invest in companies that are truly globally scalable and can improve health outcomes or cure disease.
At ARTIS we invest in data-driven life sciences companies that solve problems affecting everyday people from across the globe. We care about scalable medical technologies backed by engineering, AI and strong datasets with broad indications for healthcare and life sciences.
Investing in companies with a TechBio thesis ensures a plethora of indications from a singular biologically engineered approach, opening the door for increased revenue streams, optionality, intellectual property and flexibility to pivot in times of need.
By combining the best of computer science and the powers of cellular biology, TechBio is the engineering-first approach that enables cures instead of treatments, personalized therapeutics, more efficient drug discovery and powerful AI-machine led exploration of biological circuitry.